Abstract |
We analyzed 56 of 75 previously untreated patients with hepatocellular carcinoma who entered on a prospectively randomized trial of acivicin versus 4'deoxydoxorubicin ( esorubicin). At least one episode of severe toxicity was documented in 23% of the patients on acivicin and 45% of those on 4'deoxydoxorubicin. Two patients responded to 4'deoxydoxorubicin. One response was partial, lasting 58 weeks, and one was complete, lasting more than 4 years. The 90% confidence interval for response is 1-20%. In view of a 45% rate of severe or worse toxicity with 4'deoxydoxorubicin, this drug cannot be recommended as treatment. There were no responses on acivicin.
|
Authors | G Falkson, A Cnaan, I W Simson, Y Dayal, H Falkson, T J Smith, D G Haller |
Journal | American journal of clinical oncology
(Am J Clin Oncol)
Vol. 13
Issue 6
Pg. 510-5
(Dec 1990)
ISSN: 0277-3732 [Print] United States |
PMID | 2173394
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibiotics, Antineoplastic
- Isoxazoles
- Doxorubicin
- acivicin
- esorubicin
|
Topics |
- Antibiotics, Antineoplastic
(administration & dosage, adverse effects, therapeutic use)
- Carcinoma, Hepatocellular
(drug therapy, mortality)
- Doxorubicin
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Drug Administration Schedule
- Female
- Humans
- Isoxazoles
(administration & dosage, adverse effects, therapeutic use)
- Liver Neoplasms
(drug therapy, mortality)
- Male
- Prospective Studies
- Survival Rate
|